ARAY ACCURAY INC
Debt Financing ·
Accuray's lenders waived two defaults under its financing agreement, and the same amendment exchanges converted debt for preferred shares and penny warrants, subject to shareholder approval.
We have not published a story on ACCURAY INC yet. When there is news, it will appear here.
Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports treatment delivery, planning, imaging and data management solutions. Its portfolio includes the CyberKnife robotic platform and a helical portfolio of Accuray Stellar, Radixact, Accuray Helix and Tomo C systems, where available. Its systems are designed to support SRS, SBRT, IMRT, IGRT and adaptive radiation therapy, with software for motion management, treatment planning, anatomical change detection and retreatment planning. ClearRT helical kVCT imaging is available on selected systems and configurations. The CyberKnife platform is also used by neurosurgeons for radiosurgery of brain and spine tumors, and for selected neurologic and endocrine disorders where clinically appropriate. The company also provides customer support, installation, training and other professional services. Accuray was incorporated in California in 1990, reincorporated in Delaware in 2007, and has its principal United States office in Madison, Wisconsin.
| Product or program | What it is | Stage |
|---|---|---|
| CyberKnife | Robotic radiation therapy platform | |
| Accuray Stellar | Helical radiation therapy system with motion management | |
| Radixact | Helical radiation therapy system | |
| Accuray Helix | Helical radiation therapy system |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Revenue | $401.9 million | $458.5 million |
| Research and development | $37.8 million | $47.9 million |
| Net income (loss) | -$49.2 million | -$1.6 million |
| Cash from operations | -$7.0 million | $2.9 million |
| Cash and equivalents | $40.6 million | $57.4 million |
ACCURAY INC trades under the ticker ARAY on NASDAQ.
ACCURAY INC is listed on NASDAQ.
Our directory records ACCURAY INC under United States.
aibio.space lists ACCURAY INC among 2,820 public biotech companies and publishes its news here as stories appear.
Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports treatment delivery, planning, imaging and data management solutions. Its portfolio includes the CyberKnife robotic platform and a helical portfolio of Accuray Stellar, Radixact, Accuray Helix and Tomo C systems, where available.
CyberKnife: Robotic radiation therapy platform Stage: stage not stated.
Accuray Stellar: Helical radiation therapy system with motion management Stage: stage not stated.
$401.9 million for the fiscal year ended Jun 30, 2026, as reported to the SEC.
ACCURAY INC reported a net loss of $49.2 million for the fiscal year ended Jun 30, 2026, and used $7.0 million of cash in operations, per its annual report to the SEC.
$37.8 million in the fiscal year ended Jun 30, 2026, per its annual report.
$40.6 million in cash at Jun 30, 2026, per its 10-K.
Our latest story on ACCURAY INC, dated Jul 29, 2026: "Accuray gets lender waiver of defaults under financing agreement". Accuray's lenders waived two defaults under its financing agreement, and the same amendment exchanges converted debt for preferred shares and penny warrants, subject to shareholder approval. Source.
Our latest debt story, dated Jul 29, 2026: "Accuray gets lender waiver of defaults under financing agreement". Accuray's lenders waived two defaults under its financing agreement, and the same amendment exchanges converted debt for preferred shares and penny warrants, subject to shareholder approval. Source.
Press Follow on this page to add ACCURAY INC to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming ACCURAY INC so far, in Debt Financing.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio